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SUSTAINED ELEVATION OF POSTPRANDIAL GLP-1 AFTER 
BARIATRIC SURGERY 
JUSTIN R. PUCKETT 
ABSTRACT 
 The incidence of obesity is on the rise globally and is associated with 
many comorbidities, especially type 2 diabetes mellitus (T2DM). Bariatric 
surgery is the most effective intervention for weight loss and reducing obesity-
associated morbidity. The most common bariatric surgeries are roux-en-Y gastric 
bypass (RYGB) and sleeve gastrectomy (SG). RYGB and SG are equally 
efficacious at long-term reduction of weight in obese individuals and 
amelioriation of T2DM. Interestingly, the improvement of glucose regulation is 
noted before weight loss is observed. The most likely mechanism underlying 
glucose homeostasis after bariatric surgery is hormonal changes in the intestine. 
Enteroendrocrine changes favorable of an anti-diabetic profile are noted after only 
a few days of receiving either RYGB or SG surgery. Most consistently, elevated 
postprandial GLP-1, a potent regulator of appetite and glucose control, is 
observed in post-bariatric surgery patients. However, data is limited regarding 
post-prandial GLP-1 levels beyond two years after surgery. This study will 
address the gap in literature by assessing postprandial elevations of GLP-1 
following RYGB or SG for up to five years. We will recruit obese type-2 
diabetics from an outpatient bariatric surgery clinic at Boston Medical Center 
  vi
scheduled to receive RYGB or SG and periodically assess postprandial GLP-1 
levels to determine if they remain elevated after 5 years. Additionally, we will 
provide evidence if there is a correlation among changes in postprandial GLP-1, 
weight loss, and hemoglobin A1c at five years. Our proposed study will help 
direct researchers to develop safer and more efficacious interventions for obesity 
and T2DM.  
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INTRODUCTION 
Background 
With type 2 diabetes mellitus (T2DM) on the rise, a search for more 
successful interventions is warranted. First-line interventions for T2DM, such as 
diet and exercise, are not always efficacious in those with severe obesity.1 
Improvement in diet and exercise only result in a loss of 10% of one’s initial 
weight, which nearly all individuals regain after 5 years.1 Bariatric surgery is 
usually performed on obese individuals who are refractory to more conservative 
weight-loss interventions. The most common bariatric surgeries are Roux-en-Y 
gastric bypass (RYGB) and sleeve gastrectomy (SG).2 RYGB and SG have been 
shown to result in profound weight loss and improvement in chronic co-
morbidities, especially T2DM.2,3 Up to 30% of patients who receive bariatric 
surgery have T2DM and usually discontinue their anti-diabetic medications post-
operatively.4,5 Up to 80% of those with T2DM who receive RYGB or SG 
experience complete remission.2,5–7 Interestingly, improvement in glycemic 
control is noted after bariatric surgery, independent of weight loss.8 The rapid and 
marked improvement in glucose regulation after surgery has raised questions as to 
the underlying mechanism.  
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Statement of the Problem 
Existing literature has identified changes in gut hormones following 
bariatric surgery as a possible explanation for the improvement of glucose 
regulation but research regarding long-term follow-up is limited. Specifically, 
postprandial GLP-1, an enteroendocrine hormone believed to be responsible for 
weight-loss-independent improvement of glucose homeostasis, has not been 
evaluated beyond two years after surgery. Further evidence is needed regarding 
the sustained elevations of postprandial GLP-1 levels following either RYGB or 
SG.  
 
Hypothesis 
We hypothesize elevations of postprandial GLP-1 observed following 
bariatric surgery will be sustained over five years.  
 
Objectives and specific aims 
Additional studies are needed to better understand the role of hormonal 
changes in the gut following bariatric surgery and their effect on glucose 
regulation. This information is critical in creating novel interventions for both 
obesity and T2DM. The objective of this study is to evaluate the role changes in 
gut hormones following bariatric surgery have on the amelioration of type 2 
diabetes mellitus. Specific aims of this study are as follows: 
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1.) Provide a literature review regarding obesity, diabetes, and changes in gut 
hormones following bariatric surgery. 
2.) Provide further evidence RYGB and SG are effective at inducing weight 
loss and amelioration of T2DM for up to 5 years.  
3.) Provide further evidence that GLP-1 remains elevated up to five years 
following RYGB or SG. 
4.) Determine if there is any correlation between changes of postprandial 
GLP-1 from baseline compared to changes in weight or A1c from 
baseline.  
 
REVIEW OF THE LITERATURE 
Overview 
Obesity  
Obesity (BMI >30 kg/m2) is on the rise worldwide, especially in the 
United States. Over 30% of those older than 18 years old in the United States are 
obese and it’s estimated this number may reach 50% by 2030.9 Additionally, 
around 20% of adolescents are obese in the United States.10 In 2009 the CDC 
estimated healthcare costs of obesity were around $147 billion. Healthcare costs 
of obesity are comprised of direct, such as preventive, diagnostic, and treatment 
services, and indirect costs, associated with morbidity and mortality. With costs of 
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healthcare and incidence of obesity increasing, the United States must find a way 
to better address these issues.  
One potential cause for the increased rates of obesity is an adoption of a 
Western lifestyle, a decrease in physical activity and increase in consumption of 
carbohydrate-dense foods.10 Obesity develops when individuals remain in a state 
of positive calorie balance, where consumption of calories exceeds expenditure.10 
Genetics are also responsible for the development of obesity.11  Studies searching 
for specific genes associated with obesity have found genes associated with brain 
signaling, suggesting obesity develops from a disruption in neurocognition rather 
than adiposity disease.11 Hormonal changes may also attribute to development of 
obesity.12 Many metabolic disturbances, such as impaired leptin and insulin 
signaling, are observed in those who are obese.10 Impairment in these hormones 
results in dysfunction of appetite control and leads to significant obesity-
associated metabolic disease.10 Aside from rare obesity-causing diseases, such as 
leptin deficiency, there is little evidence regarding the mechanism underlying 
development of hazardous obesity (BMI>40).10  
 
Interventions to treat obesity 
First-line interventions, such as improving diet or increasing physical 
activity, can offer significant weight loss of about 10% initial weight to obese 
individuals, which is almost always transient.10 Pharmacologic interventions, such 
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as absorption inhibitors or appetite suppressants, are minimally efficacious and 
are commonly accompanied with side effects such as fatigue, depression, nausea, 
abdominal pain, and insomnia.10 Absorption inhibitors work by reducing the 
amount of fat our body can absorb from food by decreasing the amount of lipase 
our pancreas secretes. Researchers developing novel pharmacologic interventions 
have not yet found a safe way to overcome the body’s robust response to a caloric 
deficit.10 Many who lose weight struggle with strong drives to eat, resulting in 
weight regain to their original weight.10 The underlying mechanisms of the strong 
desire to eat arise from the physiology of the gut.10 
 
Energy homeostasis 
The liver, adipose tissue, and gastrointestinal tract produce many short and 
long acting hormones which inform the body of its energy status.10 Energy status 
may be thought of as a positive or negative caloric balance. Multiple hormones 
(Table 1) act throughout the body, influencing food intake and energy 
expenditure. Normally, consumption of food will generate signals to inhibit 
feeding and promote digestion or energy utilization.10 However, those with a BMI 
>35 have impairments in these hormonal signals resulting in increased appetite 
and decreased energy utilization.10 Additionally, obese individuals have a 
dysfunctional entero-insular axis, or impairment in communication between the 
intestines and pancreas, increasing their risk of developing insulin resistance.10  
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Table 1. Characteristics of hormones affecting glucose regulation 
Hormone Origin Stimuli Appetite 
Effect 
Function 
GLP-1 L-cells Food 
ingestion 
Decrease -Insulin 
secretion 
-Delays gastric 
emptying 
-Increases 
beta-cell mass 
PYY L-cells Food 
ingestion 
Decrease -Delays gastric 
emptying 
CCK I-cells Fat and 
protein 
consumption 
Decrease -Gallbladder 
contraction 
-Delays gastric 
emptying 
-Pancreatic 
enzyme 
secretion 
Ghrelin Fundus and 
body of 
stomach 
Fasting Increase -Increases 
gastric 
emptying 
GIP K-cells in GI 
mucosa 
Nutrients in 
gut lumen  
Decrease -Promotes 
insulin and 
glucagon 
secretion 
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Endocrine signaling 
GLP-1 
GLP-1 is a hormone released from L-cells which are mostly found in the 
distal intestine.13 The L-cells are activated by contact with nutrients passing by 
the lumen.13 GLP-1 is categorized as an incretin, which helps pancreatic beta-cells 
secrete insulin in response to glucose.14 Additional roles of GLP-1 include 
reducing appetite, delaying gastric emptying, and increasing the size of pancreatic 
beta-cells.15 Obese individuals with T2DM have decreased postprandial GLP-1 
levels compared to those with a normal BMI and without T2DM.16–18 Toft-
Nielsen et al. have demonstrated that continuous infusion of GLP-1 in T2DM 
individuals significantly improves glucose homeostasis, reduces appetite, does not 
affect blood pressure, and has no gastrointestinal side effects.17  
 
PYY 
Peptide YY (PYY) is also released from L-cells in the distal intestine 
following ingestion of food and is known to have appetite suppressing properties 
similar to GLP-1.19 Unlike GLP-1, PYY is not known to have any effect on 
insulin secretion19 but may have a role in restoration of impaired beta-cell 
function.20 PYY levels have been shown to be decreased in obesity compared to 
normal BMI individuals.20 
 
 8 
CCK 
CCK is released from I cells which predominate the duodenum and 
jejunum following ingestion of food.21 CCK is known to decrease appetite, 
stimulate contraction of the gallbladder, delay gastric emptying, and promote 
secretion of pancreatic enzymes.21 Postprandial levels of CCK are decreased in 
those who are obese and diabetic compared to healthy controls.19  
 
Ghrelin 
Ghrelin is secreted from glands in the fundus and body of the stomach.22 
Its primary role in the body is to promote the desire to ingest food.22 Ghrelin is 
elevated before consumption of a meal and is decreased after.23 Obese individuals 
are known to have difficulty suppressing ghrelin levels following a meal 
compared to non-obese individuals.24 After individuals lose a significant amount 
of weight from lifestyle changes, ghrelin has been shown to be increased both 
before and after meals.24 The increase in ghrelin following weight loss suggests 
the body employs a compensatory mechanism to resist weight loss.  
 
Glucagon 
Glucagon is released from the alpha-cells of the pancreas and functions by 
raising blood concentrations of glucose.25 Those with T2DM have inappropriate 
elevations in glucagon both before and after meals.26 Elevated levels of glucagon 
in T2DM are considered inappropriate because the elevation occurs in the setting 
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of hyperglycemia.26 Appropriate elevations of glucagon are typically seen when 
blood sugar is low.26 Type 2 diabetics usually have a higher fasting baseline blood 
sugar, which may account for changes in the activation threshold of pancreatic 
alpha-cells.26 
 
GIP 
Gastric inhibitory polypeptide (GIP) is known to stimulate secretion of 
glucagon but only at basal glucose levels.27 When blood glucose levels are 
elevated beyond basal levels, GIP has no effect on glucagon secretion and instead 
stimulates release of insulin.27 Furthermore, GIP has been shown to have a 
reduction in incretin effect in those with T2DM in contrast to GLP-1, which has 
preserved functionality.28 
 
Diabetes and Obesity 
Those who are obese are at greater risk for acquiring chronic diseases, 
increasing the risk of mortality and morbidity.29 Specifically, obesity increases the 
risk for the development of type 2 diabetes mellitus (T2DM), heart failure, liver 
disease, hypertension, hyperlipidemia, cancer, depression, obstructive sleep 
apnea, and dementia.5 A rise in the prevalence of T2DM may be a result of an 
increasing prevalence of obesity.30 
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Development of T2DM in obese individuals is related to a metabolic 
dysfunction affecting insulin signaling and appetite control.31 Adipocytes release 
proinflammatory cytokines and free fatty acids, which are damaging to the liver, 
pancreas, and intestines.31 Compared to those with a normal BMI, obese 
individuals have a greater number of adipocytes, resulting in greater damage to 
the organs responsible for appetite and glucose regulation.31  
 
Type 2 diabetes mellitus 
The prevalence of diabetes in the United States ranges from 6-12% of 
adults with T2DM accounting for around 90% of these cases.32 The diagnosis of 
T2DM is made when an individual has a glycosylated hemoglobin A1c of greater 
than 6.5%, a three month reflection of the body’s ability to regulate glucose.32 
Additionally, a two hour oral glucose tolerance test greater than 200 mg/dL or two 
fasting blood sugars greater than 126 mg/dL will make the diagnosis.32  
T2DM is commonly seen in obese adults, not genetically inherited, and 
characterized by an insulin insensitivity.32 Insulin insensitivity occurs when the 
body’s insulin receptors require more insulin stimulus for glucose to enter cells, 
compared to nondiabetic individuals.32 Only about 16% of T2DM require 
insulin.32  
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T2DM Interventions 
First-line interventions for T2DM are similar to interventions already 
discussed for obesity, such as diet and exercise modifications.33 Weight loss 
provides significant physiologic improvement of glucose regulation in those with 
T2DM but is not shown to be effective in the long-term in preventing acquisition 
of T2DM.30 For example, obese individuals may lose weight, improving their 
ability to regulate glucose, but still have significant ongoing adipocyte-induced 
organ damage, which eventually will lead to insulin insensitivity.  
There are a wide variety of pharmacologic interventions for T2DM. 
Generally, individuals are first started on metformin, which acts to reduce hepatic 
gluconeogenesis.32 Additionally, individuals may be started on medications which 
help the body secrete insulin, inhibit intestinal reabsorption of glucose, increase 
urinary glucose excretion, or improve sensitivity to insulin.32 If these medication 
do not help the individual achieve a goal HgbA1c of less than 7.0%, then insulin 
therapy may be initiated.32  
 
Bariatric surgery and obesity 
Failure of first line therapies and limited pharmacologic interventions call 
for more efficacious treatments, such as surgery. The most effective treatment for 
both losing and maintaining healthy weight is bariatric surgery.33 Generally, 
individuals who undergo bariatric surgery lose around 50-70% of excess body 
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weight.2 However, around 20% of bariatric surgery patients fail to lose a 
significant amount of weight; the underlying reason remains unclear.34 The 
mechanism for surgically-induced weight loss is primarily attributed to appetite 
and caloric intake reduction.35 Despite patients’ negative calorie balance 
following bariatric surgery, they report greater degrees of satiety.15 
The most common bariatric surgeries are the roux-en-Y gastric bypass 
(RYGB), and sleeve gastrectomy (SG).35 The RYGB incorporates both restrictive 
and malabsorptive components, while the while the SG is considered only 
restrictive.30 The restrictive component, shared by both RYGB and SG, arises 
from resection of the stomach. The stomach resection results in less space for 
food and earlier sensation of satiety. RYGB provides an additional malabsorptive 
component by bypassing the duodenum where significant amounts of nutrient 
absorption takes place.  
 
Indications/contraindications for bariatric surgery 
Generally, bariatric surgery is indicated for those who have a BMI >40 
kg/m2 or BMI >35 kg/m2 with at least one associated comorbidity, such as 
hypertension, hyperlipidemia, obstructive sleep apnea, T2DM, asthma, or 
gastroesophageal reflux disease.36 Additionally, bariatric surgery is indicated for 
those with a BMI between 30-35 with uncontrolled T2DM or metabolic 
syndrome. Relative and absolute contraindications for bariatric surgery include 
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age of less than 18 or greater than 65, severe coagulopathy, severe cardiac 
disease, current drug or alcohol abuse, untreated major depression or psychosis, or 
uncontrolled eating disorders. Furthermore, individuals who are unable to adhere 
to a strict diet rich in vitamins and nutrients should not receive the surgery. 
Generally, individuals with a BMI <27 are not offered the surgery.  
 
Preoperative predictive factors for T2DM remission 
The ABCD score is a validated tool used to assess the likelihood of T2DM 
remission after bariatric surgery.30 It is comprised of the patient’s age, BMI, C-
peptide level, and duration of disease.30 Those who have been diabetic for shorter 
lengths of time are more likely to receive improved glucose regulation from the 
surgery.40 Bariatric surgery for individuals with a BMI <27 provides minimal 
benefits and is contraindicated for this population, as previously mentioned.30 C-
peptide is a byproduct of insulin and can be measured to assess how much insulin 
a person is producing or give an estimate of pancreatic beta-cell mass.30 Those 
with advanced age usually do not receive as much improvement in glucose 
regulation than those who are younger.30 
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Bariatric Surgery and T2DM 
Bariatric surgery has also been shown to be the most effective treatment 
for T2DM in obese individuals with remission rates up to 80%.5–7 The 
mechanisms for T2DM resolution in bariatric surgery patients are not clearly 
understood, as this effect is observed independent of weight loss.37–39 There are 
two major hypotheses to explain this phenomenon: the hindgut hypothesis and the 
foregut hypothesis.30 The hindgut hypothesis proposes the weight loss-
independent improvement of glucose regulation comes from increased production 
of anti-diabetic hormones in the distal intestine.30 After surgically bypassing the 
foregut, more undigested food reaches the hindgut stimulating enteroendocrine 
cells to produce anti-diabetic hormones, such as GLP-1.30 The foregut hypothesis 
proposes less anti-incretin and appetite-stimulating hormones are produced in the 
proximal intestine when bypassed by bariatric surgery.30  
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Existing Research 
RYGB vs SG efficacy in weight loss and remission of T2DM 
Literature regarding the comparative efficacies of RYGB and SG is 
extensive and summarized in Table 2. Generally, RYGB and SG do not differ 
significantly in weight loss or remission of T2DM, suggesting the surgeries are 
equally efficacious.35,41–48 One meta-analysis showed no difference in weight loss 
or remission of T2DM among RYGB compared to SG.45 However, there are two 
studies which demonstrate differences in efficacy, suggesting potential superiority 
of RYGB.49,50 Lee et al. conducted a 1-year randomized controlled trial involving 
60 moderately obese (25 < BMI < 35) subjects with poorly controlled T2DM 
(HbA1c >7.5%) who were randomly assigned to RYGB (n=30) or SG (n=30). 
They demonstrated a significantly greater number achieving remission of T2DM 
12 months after RYGB compared to SG and significantly more weight loss in the 
RYGB group.50 Kashyae et al. showed a similar superiority of T2DM remission 4 
weeks after RYGB (n=9) compared to SG (n=7) but without any significant 
difference in weight loss among the two surgical groups in a prospective cohort 
study.49 The largest prospective study involving 558 subjects by Zhang et al 
followed obese T2DM subjects for 1 year after either RYGB (n=358) or SG 
(n=200), however, revealed no significant difference in weight loss or remission 
of T2DM.47 
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Table 2. A comparison of significant weight loss and amelioration of type 2 
diabetes mellitus following roux-en-Y gastric bypass vs sleeve gastrectomy 
Method Author Study Follow-
up 
Subject 
# 
Wt 
loss 
T2DM 
RYGB 
SG 
Lee et al. RCT 1 year 30 
30 
ꜜꜜ 
ꜜ 
ꜜꜜ 
ꜜ 
RYGB 
SG 
Kashyap 
et al. 
Prospective 4 weeks 9 
7 
ꜜ 
ꜜ 
ꜜꜜ 
ꜜ 
RYGB 
SG 
Abbatini 
et al. 
Retrospective 3 years 16 
20 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Vidal et 
al. 
(2007) 
Prospective 4 months 50 
35 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Cutolo et 
al. 
Retrospective 2 years 16 
15 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Yip et al. Meta-
analysis 
Up to 3 
years 
998 
179 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Leyba et 
al. 
Prospective 1 year 75 
42 
ꜜ 
ꜜ 
N/A 
RYGB 
SG 
Zhang et 
al. 
Prospective 1 year 358 
200 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Kokkinos 
et al. 
Prospective 6 months 14 
23 
ꜜ 
ꜜ 
N/A 
RYGB 
SG 
Nocca et 
al. 
Prospective 1 year  35 
33 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
RYGB 
SG 
Vidal et 
al. (2008) 
Prospective 1 year 52 
39 
ꜜ 
ꜜ 
ꜜ 
ꜜ 
One arrow is used to indicate a significant decrease while two arrows are used to 
indicate a significantly greater significant decrease. N/A= not assessed. 
 
Elevated GLP-1 as a mechanism for improved glucose homeostasis 
One potential mechanism for the significant improvement in glucose 
regulation is a hormonal change in the gut following bariatric surgery.10,30,38 There 
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is a large amount of research demonstrating elevated postprandial levels of GLP-1 
following either RYGB or SG5,6,29,33,51–59 (Table 3). The largest study, by Jimenez 
et al., recruited 153 subjects with T2DM who were scheduled to undergo RYGB 
or SG.52 Among study participants, 75% experienced remission of T2DM for up 
to one year, defined as hemoglobin A1c <6.5%, without a statistical significant 
difference between surgical groups.52 In both surgical groups, postprandial GLP-1 
was elevated compared to baseline after surgery while fasting levels remained 
unchanged.52 Additionally, Jimenez et al. demonstrated an association between 
T2DM remission and elevated postprandial GLP-1 levels.52 The evidence 
provided by the study is consistent with others and suggests GLP-1 plays a role in 
improvement of glucose regulation following bariatric surgery. 
Two studies have demonstrated a significantly greater postprandial GLP-1 
response following RYGB compared to SG33,56. One of the studies, a randomized 
prospective study by Peterli et al., assigned either RYGB (n=13) or SG (n=14) to 
patients.33 Their study showed early improvement in glucose regulation at one 
week in both groups without a statistical significant difference among the two 
surgeries.33 However, there was a greater postprandial GLP-1 response in the 
RYGB group.33 Of note, this study is likely underpowered given their small 
sample size. Consistent with other studies, both groups did not show any 
statistical difference compared to controls in their fasting GLP-1 levels.29,33,54,56 A 
present limitation of research regarding GLP-1 is a lack of long-term follow-up to 
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provide evidence that the elevations of postprandial GLP-1 are sustained beyond 
two years.  
 
Table 3. Comparison of fasting and postprandial GLP-1 and PYY following 
roux-en-Y or sleeve gastrectomy 
Meth
od 
Author Study 
Methodol
ogy 
Samp
le  
size 
Fasti
ng 
GLP-
1 
Fasti
ng 
PYY 
Postprand
ial GLP-1 
Postprand
ial 
PYY 
RYG
B 
Rodieux et 
al. 
CS 8 NC NC ꜛ ꜛ 
RYG
B 
Le Roux et 
al. 
Prosp 12 NC NC ꜛ ꜛ 
RYG
B 
Borg et al. Prosp 6 NC NC ꜛ ꜛ 
RYG
B 
SG 
Peterli et 
al. 
Prosp 
Rand 
12 
11 
NC NC ꜛꜛ 
ꜛ 
ꜛ 
ꜛ 
RYG
B 
SG 
Yousseif 
et al. 
Prosp 10 
8 
NC NC ꜛꜛ 
ꜛ 
ꜛꜛ 
ꜛ 
RYG
B 
SG 
Ramon et 
al. 
Prosp 
Rand 
7 
8 
NC NC ꜛ 
ꜛ 
ꜛ 
ꜛ 
RYG
B 
Vidal et al. CS 24 NC N/A ꜛ N/A 
RYG
B 
SG 
Jimenez et 
al. 
Prosp 98 
55 
NC N/A ꜛ 
ꜛ 
N/A 
RYG
B 
SG 
Nannipieri 
et al. 
Prosp 23 
12 
NC NC ꜛ 
ꜛ 
ꜛ 
ꜛ 
RYG
B 
Bose et al. Prosp 11 NC N/A ꜛ N/A 
RYG
B 
Laferrere 
et al. 
Prosp 8 NC N/A ꜛ N/A 
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RYG
B 
SG 
Karamana
kos et al. 
Prosp 16 
16 
N/A NC N/A ꜛ 
ꜛꜛ 
CS=Cross-sectional; Prosp=prospective cohort; Rand=randomized controlled 
trial; NC=no change; N/A=not assessed; ꜛ=significant increase; ꜛꜛ=significantly 
greater significant increase 
 
PYY in weight reduction and glucose regulation 
Peptide YY3 (PYY) is another gut hormone believed to be involved in the 
reduction of weight and possibly improvement in glucose regulation following 
bariatric surgery.14 Following RYGB or SG, levels of PYY have been shown to 
be elevated after ingestion of a meal while fasting levels remain unchanged (Table 
3).29,54–60 One of the studies showed a greater postprandial PYY response 
following RYGB compared to SG,56 while seven other studies showed no 
significant difference among the two surgical groups.29,33,54 Yousseif et al. 
recruited 18 obese non-diabetic females in a prospective study undergoing RYGB 
(n=10) or SG (n=8), matched subject’s adiposity among the two groups, and 
found a significantly greater postprandial PYY response in the RYGB group 
compared to SG.56 Despite this one study showing superiority in RYGB, it likely 
was underpowered given the small sample size. The majority of studies show no 
difference in PYY following bariatric surgery.29,54–56,58,60 It has also been shown 
those who fail to lose a significant amount of weight following RYGB have lower 
circulating levels of PYY.57  
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Ghrelin is significantly reduced following SG 
Given the intimate relationship of obesity and T2DM, it is important to 
further examine the effects of ghrelin, before and after bariatric surgery. Studies 
regarding ghrelin levels following RYGB or SG are inconclusive but generally 
show decreased levels after SG but not after RYGB.22,54,55,60 Karamanakos et al. 
performed a prospective double blind study which examined 6 month 
postoperative ghrelin levels following bariatric surgery in 32 patients.54 Subjects 
were assigned to each surgical group (16 each) with a significant decrease in 
hunger stimulating ghrelin levels in those who underwent SG but no difference 
among those who received RYGB.54 Conversely, Holdstock et al. recruited 66 
subjects undergoing RYGB in a prospective study and revealed significantly 
increased ghrelin levels following surgery.61 Similarly, Ramon et al. demonstrated 
decreased fasting and postprandial ghrelin levels in those undergoing SG but no 
difference in those who received RYGB.29 Other studies have shown significantly 
decreased ghrelin levels following RYGB compared to controls.22,58 In summary, 
levels of ghrelin are typically decreased following bariatric surgery although there 
have been some reported elevations after RYGB.  
 
CCK levels after bariatric surgery are inconclusive 
There are few studies evaluating the effect bariatric surgery has on CCK 
levels and the results remain inconclusive. Rubino et al. demonstrated no change 
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in circulating levels of CCK following RYGB at 6 weeks follow-up in 10 
morbidly obese patients.62 Similarly, another study by Kellum et al. recruited 
morbidly obese subjects assigned to either RYGB (n=9) or vertical banded 
gastroplasty (n=7) and found no difference in postprandial CCK levels at 6 
months compared to controls or among surgical groups.63 A more recent study by 
Jacobsen et al. recruited 8 non-diabetic obese subjects and found a significantly 
increased secretion of CCK after ingestion of a meal within two weeks of 
RYGB.64 A 2013 cross-sectional study by Dirksen et al. of RYGB subjects 
revealed significantly increased postprandial CCK levels in 17 individuals who 
failed to lose significant weight (defined as <50% excess BMI) compared to 16 
individuals who experienced significant weight loss (defined as >60% excess 
BMI).65 In a study comparing postprandial CCK, obese subjects were randomly 
assigned to either RYGB (n=12) or SG (n=11) and demonstrated increased levels 
at 1 year follow-ups but to a greater degree in the SG group.60  
 
GIP is increased or unchanged following bariatric surgery 
Research regarding GIP levels after bariatric surgery is limited and 
inconclusive; studies have reported increases following surgery, whereas others 
have shown no change.5,6,38,49,66,67 Romero et al. conducted a prospective study in 
12 obese diabetic subjects who were receiving either RYGB (n=6) or SG (n=6) 
and revealed a significant increase in postprandial GIP levels in the SG group six 
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weeks after surgery but no change in the RYGB group.38 Conversely, Laferrere et 
al. conducted two studies in subjects undergoing RYGB (N= 9 and 8) and showed 
increased levels of postprandial GIP one month following the surgery in both 
studies.5,66 A prospective study by Kashyap et al. found no difference in 
postprandial GIP levels 1 month following either RYGB (n=9) or SG (n=7) in 
obese T2DM subjects.49 Hansen et al. also found no difference in postprandial 
GIP levels in 9 diabetic obese subjects six weeks following RYGB.67 Bose et al. 
conducted a prospective study with 11 obese subjects with T2DM, which showed 
elevated postprandial GIP levels one month following surgery with no change at 
one year follow-ups.6 More research is needed to help determine the affect 
bariatric surgery has on GIP levels given that the current literature is limited and 
yields conflicting results. 
 
Glucagon levels are unchanged after bariatric surgery 
Shah et al. have shown an association between elevated levels of glucagon 
and a dysfunction in glucose homeostasis in T2DM.26 Glucagon levels following 
bariatric surgery have not been extensively studied but generally are not changed 
following RYGB.5,38,51,66,68,69 A study by Romero et al. compared RYGB (n=6) to 
SG (n=6) and found no significant difference in fasting or postprandial levels 
compared to controls.38 Other studies which looked solely at RYGB subjects 
similarly revealed a failure to suppress glucagon levels following surgery.5,51,66,69 
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Conversely, Swabrick et al. demonstrated a decrease in glucagon levels following 
RYGB in 19 diabetic obese subjects.  
 
Calorie restriction improves glucose regulation 
Another mechanism proposed for improvement of glucose regulation 
following bariatric surgery is calorie restriction.39 Isbell et al. conducted a study 
which recruited 18 obese subjects with T2DM and divided them in two groups, 
RYGB (n=9) and caloric restriction diet (n=9).39 The RYGB group had the same 
caloric restriction as the diet control group and all subjects were matched for age, 
sex, weight, and diabetes duration.39 They found improvement in insulin 
resistance among both groups without any significant difference between the 
groups.39 Thus, the study suggests that early improvement in glucose regulation is 
not dependent on gut hormonal changes but, rather, the anti-diabetic effect is due 
to calorie restriction. 
 
 Although there are clear post-surgical associations with hormones such as 
GLP-1 and weight loss or improvement in glucose regulation, the underlying 
mechanism is likely multifactorial. Additionally, the current research is limited 
regarding long-term follow-up to assess the levels of the hormones discussed 
beyond two years. Our study aims to bridge the gap in literature by assessing the 
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most consistent change noted after bariatric surgery, elevations in postprandial 
GLP-1, and evaluating it for five years.  
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METHODS 
Study Design 
This will be a prospective cohort study assessing sustained elevations of 
postprandial GLP-1 levels following RYGB or SG in individuals with T2DM.  
 
Study Population and Sampling 
Subjects will be recruited over a period of 6 months from the outpatient 
bariatric surgery clinic at Boston Medical Center. Inclusion and exclusion criteria 
(Table 4) have been established to minimize modifying factors. The estimated 
sample size for repeated measures of ANOVA is 32 with an alpha <0.05, power 
of 80%, and effect size of 0.28 in postprandial GLP-1. This effect size was 
estimated from the results of a previous study conducted by Peterli et al. assessing 
difference in postsurgical postprandial GLP-1 levels and pre-bariatric surgical 
values60 The sample size is based on 5 measures which are conservatively 
assumed to be non-correlated. Of note, correlation would increase the power of 
the study. Accounting for a loss to follow-up rate of about 20%, we will recruit 40 
subjects in our study.  
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Table 4. Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
• BMI of 35-45 
• Scheduled for RYGB or SG 
• Age 25-65 
• Using oral anti-diabetic 
medication 
• 10%> A1c >7.5% 
• Use of insulin, GLP-1 agonist, 
or DPP4 inhibitors 
• Hx of severe psychiatric 
disease, uncontrolled HTN, 
cancer, CHF, cirrhosis, 
alcoholism, drug abuse, or 
severe pulmonary disease 
 
Surgical Technique 
RYGB 
The laparoscopic RYGB will create a vertical gastric pouch of 20-30 ml 
with surgical staples in the cardia of the stomach.60 The Roux limb will be 
approximately 100 cm and the biliopancreatic limb will be approximately 50 cm 
from the ligament of Treitz, as described in a previous study.60 
SG 
The laparoscopic SG will be done along a 36 French bougie from the 
angle of His to approximately 3-4 cm proximal to the pylorus, as described in a 
previous study.60  
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Recruitment 
Individuals who meet inclusion and exclusion criteria will be recruited at 
an outpatient bariatric center affiliated with Boston Medical Center over a 6-
month period. Type of surgery will be assigned per the surgeon’s discretion and 
patient preference. We will aim to recruit an equal number of RYGB and SG 
participants. Subjects interested in participating will be briefed by one of the 
investigators to fully inform them of study details, including risks and benefits. 
Informed consent will be obtained during the visit with the investigator.  
 
Data Collection 
Individuals will be assessed within one month of surgery then 
postoperatively at three months, one year, two years, three years, and five years. 
Blood will be drawn at each of these encounters after a 12 hour fast to assess 
GLP-1 and HgbA1c. Individuals will be instructed to not take their anti-diabetic 
medications during the fast. Weight and height will be assessed at each visit to 
calculate BMI. A standard liquid meal of 350 kcals (46% carbs, 32% protein, and 
12% lipids) will be given to the subjects. Blood will be drawn at 0, 30, 60, 90, and 
120 minutes for assessment of GLP-1. GLP-1 will be measured with 
commercially-available kits, as previously described, to obtain a maximum 
plasma concentration (Pmax).60 Blood for hemoglobin A1c will be drawn at each 
visit and sent to Quest Diagnostics for evaluation.  
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Data Analysis 
Data analysis will be performed using SPSS 15.0. Values will be reported 
as means +/- standard error of the mean (SEM). Repeated measures analysis of 
variance (ANOVA) will be used to assess for significant differences in 
longitudinal levels of GLP-1 after surgery, overall and stratifying for type of 
surgery. If a significant difference is noted, then post hoc analysis using a 
pairwise comparison of all measures will be conducted, adjusting alpha using the 
Bonferroni correction. To verify there is a significant change of pre- and post-
operative postprandial GLP-1, a paired t test will be performed at 1 year. At 5 
years, Spearman correlations between the change in GLP-1 from baseline to the 
change in weight and A1c from baseline will be assessed as secondary outcomes. 
 
Timeline 
We aim to have our research proposal approved by the IRB in the Fall of 
2018 so subjects can be recruited over a six-month period from January 2019 to 
June 2019 (Table 5). We will collect and analyze data over the subsequent five 
years from July 2019 to July 2024. Our manuscript will be submitted for peer 
review in the Fall of 2024. Resources will include investigators, statisticians, and 
surgeons.  
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Table 5. Timeline of research project 
Fall 2018 Submission and Approval by IRB 
January 2019- June 2019 Recruitment of subjects and surgery 
July 2019- July 2024 Data collection and analysis 
Fall 2024 Manuscript submitted for peer review 
 
Institutional Review Board 
This study will be submitted for full IRB review to the Boston University 
Medical Campus IRB under INSPIR II criteria and to the IRB of Boston Medical 
Center.  
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CONCLUSION 
Discussion 
With global incidence rates for both obesity and T2DM on the rise, the 
need to develop more efficacious interventions is warranted to reduce the 
associated morbidity.10 First-line therapies are not always successful in providing 
sustained weight loss.30 Bariatric surgery, however, is highly effective at inducing 
sustainable weight loss and amelioration of T2DM.34  
Interestingly, the improvement in glucose homeostasis occurs before 
significant weight loss is observed.8 The underlying mechanisms for the profound 
improvement of glucose regulation are not clearly understood but believed to be 
largely attributed to hormonal changes seen in the intestine after surgery.4 Just 
days after surgery, hormonal changes favorable of an antidiabetic profile are 
observed.4 The most consistent change noted after surgery are elevated 
postprandial GLP-1 levels.52 
GLP-1 serves multiple functions in improved glucose homeostasis. GLP-1 
acts as an incretin to restore functionality of pancreatic beta cells to appropriately 
release insulin when blood sugars are elevated.13 Additionally, GLP-1 acts to 
delay gastric emptying resulting in increased satiety.14 The elevation of 
postprandial GLP-1 observed after bariatric surgery is one of many mechanisms 
proposed for amelioration of T2DM and weight loss.  
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Bariatric surgery reorganizes the intestine in a way which alters the 
secretion of hormones in response to meals. One theory, the hindgut hypothesis, is 
more undigested food reaches the L-cells after surgery, resulting in proliferation 
of the cells and a more robust GLP-1 response.30 The restrictive and 
malabsorptive nature of the surgeries are responsible for the increase in nutrient 
signaling occurring in the intestine by altering the structure.10 The hindgut 
hypothesis supports the proposition that GLP-1 is responsible for the 
improvement in glucose regulation observed independent of weight loss.   
Mechanisms underlying weight regain following bariatric surgery remain 
elusive but are believed to be attributed to lifestyle, psychiatric, hormonal, and 
surgical factors.70 Individuals who are minimally physically active or do not 
adhere to a postsurgical diet are more likely to experience weight regain than 
those who exercise 30 minutes per day and consume a healthy diet rich in 
protein.70 Psychological disorders, particularly eating disorders, have been 
associated with weight regain.70 One study showed one half of those who 
experienced weight regain suffered from a binge-eating disorder.71 Hormonal 
changes after surgery are also believed to contribute to weight regain.70 One study 
demonstrated low levels of postprandial GLP-1 to be associated with weight 
regain.72 Surgical factors such as pouch dilatation, increased stoma size, and 
gastro-gastric fistulas have been recognized as mechanisms for weight regain 
following RYGB.70  
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In our present study, we propose to address the gap in existing literature 
regarding elevated postprandial GLP-1 levels beyond 2 years after surgery. There 
has been a significant weight regain observed 2-5 years after surgery.70 It is 
possible there is an underlying hormonal mechanism responsible for the regain of 
weight. Our study will measure postprandial GLP-1 levels up to 5 years after 
surgery and determine if there is any correlation with changes in weight or 
hgbA1c.  
Further studies should assess the other hormones discussed in the literature 
review such as PYY, glucagon, GIP, ghrelin, and CCK. These hormones control 
glucose regulation and appetite control and will be helpful in understanding the 
mechanisms involved in weight regain and amelioration of T2DM.14 Specifically, 
levels of these hormones should similarly be assessed over a period of 5-years to 
determine if there is a correlation between change in weight or hgbA1c. Further 
information quantifying the hormonal changes following bariatric surgery will 
provide insight as to why individuals regain weight and maintain remission of 
T2DM. 
It is of interest for future studies to also include an analysis of adipokines 
not mentioned in this study, such as TNF-alpha, IL-6, and leptin. These 
adipokines are involved in obesity-related insulin impairment.31 Although weight 
regain is relatively common in 20% of individuals, recurrence of T2DM is much 
less so.34 Further research is needed to better understand why individuals may 
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regain weight but do not appear to have a concomitant impairment of glucose 
regulation.  
Strengths of this present study include a sample size with greater than 80% 
power, consistency in surgical technique, and an ethnically diverse community. 
This study provides insight into the mechanisms underlying weight loss and 
glucose homeostasis over a longer period than most current studies. One 
limitation is not providing an analysis of additional hormones, which may be 
acting as modifying factors; however this also serves as a strength by reducing the 
likelihood of alpha errors.  
 
Summary 
The incidence of obesity and T2DM are on the rise and are usually 
refractory to first-line interventions. Bariatric surgery is highly efficacious at 
inducing sustained weight loss and improvement in blood sugar regulation. 
Enteroendocrine changes in postprandial GLP-1 levels following bariatric surgery 
have been associated with weight loss and amelioration of T2DM. Whether these 
changes are sustained beyond 2 years after surgery has not been adequately 
addressed. Our study will address this by assessing postprandial GLP-1 levels for 
up to 5 years following surgery. Additionally, we will assess the findings at 5 
years to determine if there is an association with change in weight or A1c. Given 
a period of weight regain typically observed 2-5 years following surgery, we 
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suspect postprandial GLP-1 will be elevated during the first two years of weight 
loss and improvement in glucose regulation will then significantly decrease 
during a period of weight regain. However, if weight regain does not occur, then 
we suspect the elevations of postprandial GLP-1 will be sustained and associated 
with improved HgbA1c.  
 
Clinical and/or public health significance 
Understanding the mechanisms responsible for improvement in glucose 
regulation or weight loss helps researchers develop more efficacious interventions 
for obesity and T2DM, two significant public health issues. Additionally, 
assessing postsurgical enteroendocrine beyond 2 years specifically may unmask a 
potential mechanism for the period of weight regain typically observed 2-5 years 
following bariatric surgery.  
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